Biotech Falls Again as Celgene Suffers

By Ben Levisohn Celgene (CELG) today reported above-consensus earnings today but that wasn’t enough to lift its shares–or head off another biotech selloff. Remember, yesterday the iShares Nasdaq Biot...

3 Reasons Celgene Will Bounce Back This Year

By Dan Carroll | More ArticlesApril 23, 2014 | The market’s up-and-down performance in 2014 has taken its toll on the biotech sector, and big biotech Celgene (NASDAQ: CELG  ) hasn’t been ...

Stocks End Six-Day Win Streak As Techs Sell Off

Wall Street snapped a six-day win streak Wednesday as software and medical stocks sold off. The Nasdaq dropped 0.8%, the S&P 500 0.2% and the Dow Jones industrial average 0.1%. Volume was lower a...

[video] The Top Ten Stocks for April 23

Two percent. — number 10, facebook, down two percent. Keep it right here for the very latest when earnings come out after the bout. Number nine is netflix, down four percent. An exclusive deal ...

Gilead Sciences: “Officially a Value Stock”

By Ben Levisohn Earlier this month, RBC Capital Markets wondered whether Gilead Sciences (GILD) is actually a value stock. After last night’s earnings release, Piper Jaffray’s Joshua Schimmer and tea...

Why Amgen (AMGN) Stock Is Down Today

NEW YORK (TheStreet) — Amgen  (AMGN) shares are down -5.26% to $ 113.11 in trading on Wednesday following the release of the company’s first quarter 2014 earnings report. The biotech comp...